IBA Partners with PFAROS to Tackle PFAS Waste in Healthcare

Event summary

IBA joins the PFAROS European initiative to advance PFAS destruction in healthcare and pharmaceutical applications.
The project involves 91 partners from industry, academia, healthcare, regulatory bodies, and civil society.
IBA will co-lead end-of-life and waste-management technologies, leveraging its electron beam and Rhodotron® expertise.
The initiative is funded under the Innovative Health Initiative Joint Undertaking (IHI JU).
IBA aims to assess and develop technologies for PFAS removal and destruction from hospital and pharmaceutical wastewater.

The big picture

IBA's participation in PFAROS aligns with broader EU policy objectives to reduce environmental emissions and exposure concerns related to PFAS. The initiative underscores the growing emphasis on sustainable waste management in healthcare and pharmaceutical industries, where PFAS are widely used. IBA's role highlights the strategic importance of advanced irradiation technologies in addressing environmental challenges.

What we're watching

Technology Validation: How IBA's electron beam and Rhodotron® technology will perform in PFAS destruction.
Regulatory Alignment: Whether the initiative's outcomes will meet evolving EU environmental and healthcare regulations.
Scalability: The pace at which PFAS destruction solutions can be scaled across healthcare and pharmaceutical sectors.